I-Mab Biopharma has filed an investigational new drug (IND) application with South Korea’s Ministry of Food and Drug Safety (MFDS) to conduct a clinical trial of TJM2 for the treatment of cytokine storm in patients with severe or critical Covid-19 infection.

Cytokine storm is the immune system’s overreaction to the viral infection and leads to clinical complications in severe and critically ill Covid-19 patients.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) levels are observed to be elevated in the plasma of infected patients with cytokine storm.

TJM2 is a monoclonal antibody designed to neutralise GM-CSF.

The planned single-arm, open-label pilot clinical trial will assess the ability of TJM2 in decreasing cytokine levels, including GM-CSF, in people with severe SARS-CoV-2 infection in South Korea.

I-Mab Biopharma CEO Dr Joan Shen said: “Recent data, including safety, pharmacokinetic (PK) and pharmacodynamic (PD) results generated from a previous single ascending dose study, preclinical studies, and research by the medical and scientific community studying Covid-19-associated CS will provide science-based rationale and solid evidence to help us further explore the potential of TJM2 as an innovative treatment for CS.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Earlier this month, the company launched a similar programme in the US to develop TJM2 for treating Covid-19-related cytokine storm.

According to data from a completed Phase I single ascending dose trial in the US, the drug candidate demonstrated favourable safety, tolerability, PK/PD and immunogenicity profiles.

China’s National Medical Products Administration cleared an IND to perform a Phase Ib trial of TJM2 in rheumatoid arthritis (RA) patients.

The proposed Covid-19 study will assess the drug candidate as a potential treatment to decrease or prevent cytokine storm and neurotoxicity caused by the CAR-T therapy.